Actively Recruiting
Phase 2 Study Evaluating Nemtabrutinib for Blood Cancers Including CLL, SLL, and Lymphomas
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-27
490
Participants Needed
121
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of nemtabrutinib in adults with various blood cancers including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, Richters transformation, marginal zone lymphoma MZL, mantle cell lymphoma MCL, follicular lymphoma FL, and Waldenstrms macroglobulinemia WM. This phase 2 study is sponsored by Merck Sharp & Dohme LLC and involves two parts Dose Escalation and Confirmation Part 1 and Cohort Expansion Part 2, which includes eight disease-specific groups. Participants receive nemtabrutinib tablets orally once daily until their disease progresses or they discontinue the treatment. Part 1 focuses on finding the recommended dose and assessing safety, while Part 2 enrolls participants in specific cohorts based on their disease type and treatment history. Cohorts include various lymphoma and leukemia subtypes, with some requiring prior therapy history and measurable disease criteria. During the study, participants will be monitored regularly for side effects, disease response, and drug levels in the body. Assessments include imaging scans, biopsies, blood tests, and evaluations based on established lymphoma and leukemia criteria. The study measures outcomes such as dose-limiting toxicities, adverse events, treatment discontinuations, and objective response rates over periods ranging from weeks to several years. Participants may stay in the study for up to approximately 5 years, with ongoing monitoring to evaluate the treatments impact and safety.
CONDITIONS
Brief Title
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here